Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

May 8, 2024

https://www.globenewswire.com/news-release/2024/05/08/2877685/0/en/Kamada-Reports-Strong-First-Quarter-2024-Financial-Results-with-Year-Over-Year-Top-Line-Growth-of-23-and-a-96-Increase-in-Profitability-Raises-Full-Year-Financial-Guidance.html

REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ:KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.